Novo's $2.1B Vivtex Deal Boosts Obesity Drug Pipeline
By Al Barbarino · February 25, 2026, 1:22 PM EST
Novo Nordisk said on Wednesday it is partnering with Vivtex Corp. on a deal worth up to $2.1 billion to develop drugs for obesity and related conditions, pressing ahead with a...
To view the full article, register now.